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Abstract
 Atrial fibrillation (AF) is the most common arrhythmia and a direct cause of thromboembolic complications. 
The most common site of thrombus formation is the left auricle also referred to as the left atrial appendage 
(LAA). Pharmacotherapy with vitamin K antagonists (VKA) and non-vitamin K antagonist oral anticoagulants 
(NOACs), as well as, percutaneous and surgical interventions have all been used to prevent these complications. 
Interventional management is the treatment of choice in patients with contraindications to oral anticoagulants; 
the efficacy of such management is comparable to that of pharmacotherapy while the risk of adverse events, 
ie., severe haemorrhage or haemorrhagic stroke, is lower. Hence, some extensions to the existing indications 
for interventional treatment might be worth considering under specific clinical circumstances. A hybrid therapy 
combining left atrial appendage occlusion (LAAO) with AF ablation seems to hold particularly notable potential 
due to high therapeutic efficacy unassociated with a significant increase in complication rates. 
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Introduction
Atrial fibrillation (AF) is the most common arrhyth-
mia worldwide [1–3]. The prevalence ranges between 
1% and 2% in the general population and increases 
with age to 7% in people over 65 years and 15–20% 
in those aged ≥ 80 years [4–6]. It has been estimated 
that, by 2050, 25% of all people over the age of 45 
will have suffered at least one episode of AF [7]. AF is 
associated with a 5-fold higher risk of ischemic stroke 
[3, 8] yielding a 5% risk of ischemic stroke per year 
[3–5, 8]. Cardioembolic strokes are considered more 
lethal than other sources of strokes [9]. A vast major-
ity of cardiac thrombi are formed in the left atrial ap-
pendage (LAA) [2, 3, 10–12] and approximately 90% 
of all strokes originate from this structure [7]. LAA is 
a tubular body with a blind-ending sac. Its shape, wall 
trabeculations and AF-related compromise in left atrial 
contractile function lead to blood stasis and thrombus 
formation [5, 13, 14]. 
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The primary goal of systemic thromboembolism 
prevention is to protect the patient against the develop-
ment of the most severe AF complication, ie., ischemic 
stroke. The currently available methods for ischemic 
stroke prevention are anticoagulant pharmacotherapy, 
surgical LAA closure, percutaneous LAA occlusion, and 
ablation for atrial fibrillation. The latter cannot directly 
prevent thrombus formation but markedly restricts the 
pathomechanism thereof via reducing the incidence of 
atrial fibrillation. 
The aim of this paper is to present and compare 
the above-mentioned stroke prevention strategies and 
discuss possible combinations targeted at achieving the 
best therapy outcomes. 
Pharmacotherapy of thromboembolic compli-
cations of atrial fibrillation 
The CHA2DS2-VASc score has been recommended 
in the ESC guidelines for the assessment of stroke risk 
in patients with AF; a 0 score means low risk while 
patients with a score of 1 or more are anticoagulation 
candidates [4, 15]. Each point increase is associated 
with a higher risk of complication development. Low-
risk patients do not need antithrombotic therapy but 
those with moderate or high risk should be adminis-
tered anticoagulants [14]. A classic oral anticoagulant 
warfarin, a vitamin K antagonist (VKA), significantly 
reduces the risk of ischemic stroke. However, it incre-
ases the risk of major bleeding [5, 7, 15] unless INR 
is between 2 and 3 [3, 14]. INR monitoring and the 
resultant need for VKA therapy modification are quite 
bothersome [15], and INR level can be affected by 
a number of factors including a change in diet or medica-
tions, genetic factors, drugs and alcohol. Non-vitamin 
K antagonist oral anticoagulants (NOACs) provide an 
alternative to warfarin; their antithrombotic effect 
does not require routine monitoring [7, 15]. However, 
patients with mechanical heart valve prosthesis or 
moderate/severe mitral stenosis require anticoagula-
tion with a vitamin K antagonist and not NOACs [15]. 
Contrary to VKAs, NOACs (rivaroxaban, apixaban 
and edoxaban) selectively inhibit factor Xa in the co-
agulation cascade being more effective than warfarin 
[5, 14, 16, 17]. Compared to warfarin, rivaroxaban- 
-treated patients were at a lower risk of hemorrhagic 
stroke and lethal hemorrhage although mortality rates 
did not differ significantly between the groups. Hemor-
rhagic stroke, major bleeding and mortality rate were 
lower in patients receiving apixaban as compared to 
those receiving warfarin [3, 14, 16]. 
Another effective antithrombotic is dabigatran 
(direct thrombin inhibitor), the first NOAC approved 
for stroke prevention [15, 17]. Contrary to VKAs, 
dabigatran does not inhibit the synthesis of natural 
anticoagulant proteins, ie., protein C and protein S. At 
low doses, its effectiveness is comparable to that of 
warfarin while the risk of hemorrhagic complications 
decreases by 20%. High doses make it 35% more 
efficient than warfarin, the risks of hemorrhagic com-
plications being comparable [3, 15]. 
Therapeutic effects of aspirin and the combination 
of aspirin with clopidogrel were also studied but have 
been questioned in patients with AF [14, 15, 17]. 
However, they can be used as perioperative ”bridging” 
in patients with contraindications to even short-term 
anticoagulant therapy but still scheduled for percuta-
neous left atrial appendage occlusion [18, 19]. 
There are no studies comparing direct-acting med-
ications of the NOAC group. Hence, the selection of 
a particular NOAC can be quite challenging. Patients 
at high-risk for gastrointestinal hemorrhage should 
receive a NOAC associated with the lowest risk of 
such bleedings reported in large clinical trials. The 
patient’s condition should also be considered as well 
as adverse effects such as dabigatran-related dyspepsia. 
Other contraindications might include a risk of kidney 
failure in rivaroxaban-treated patients [17]. Obtaining 
an optimal therapeutic effect associated with the least 
amount and severity of adverse effects might require a 
patient tailored protocol with several drug and dosage 
modifications.
VKAs and NOACs are the predominant pharmaco-
logical agents for the prevention of thromboembolic 
events. Novel oral factor Xa inhibitors are being devel-
oped. The results of phase 2, randomized, dose-ranging 
study (Explore-Xa) showed that betrixaban in a dose 
of 40 and 60 mg daily had a lower rate of bleeding 
compared with warfarin [20, 21]. Similar results were 
obtained in atrial fibrillation study 2 (OPAL-2), where 
a darexaban dose of 120 mg was found to decrease 
plasma D-dimer levels [22]. 
Some proportion of AF sufferers cannot be admin-
istered oral anticoagulants, and especially long-term 
anticoagulant therapy, due to a history of life-threaten-
ing bleeding episodes [15, 23, 24]. Hence, a particular 
need for a therapy that would reduce the occurrence 
of thromboembolic events and, at the same time, lower 
the risk of bleeding. These patients might benefit from 
the percutaneous or surgical closure of the left atrial 
appendage, a protocol highly recommended by the 
current ESC guidelines. 
Atrial fibrillation ablation
AF ablation has been used for protection against 
recurrent AF episodes when oral antiarrhythmics or 
cardioversion prove ineffective [25–27].
At least 2% of anticoagulated patients with AF will 
experience a serious bleeding event per year, which 
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WATCHMAN
Another FDA-approved device for left atrial append-
age occlusion was the Watchman [32]. An initial study 
of 66 patients showed a 93% rate of successful LAA 
sealing [31]. The Watchman clinical program comprising 
several studies with more than 2,400 patients and 5,931 
patient-years of clinical evidence confirmed 90-95% 
efficacy of the device in LAA closure and its advantage 
over warfarin regarding the following clinical aspects: 
prevention of haemorrhagic stroke, cardiovascular 
death of unknown cause and major bleeding unrelated 
to the procedure [12]. A meta-analysis carried out by 
Reddy et al. [19] revealed that the overall mortality of 
Watchman-implanted patients was significantly lower 
compared to the warfarin cohort. The ASAP study also 
confirmed the advantage of Watchman use in patients 
with contraindications for even short-term anticoagu-
lation therapy and those intolerant of long-term oral 
anticoagulants. All this was incorporated in the FDA’s 
recommendations regarding the indications for the 
Watchman device [12, 19]. 
Amplatzer
The Amplatzer Cardiac Plug (ACP) is a device that 
was originally designed for closure of atrial septal defect 
and not for LAA sealing [13]. Although no randomized 
studies have been carried out so far, the clinical data 
from the ACP multicenter registry including 1,047 pa-
tients revealed that procedural success was achieved in 
97 to 98%. The risk of stroke and bleeding unrelated 
to the procedure was lower than that estimated based 
on CHA2DS2-VASc and HAS-BLED [11, 25, 33]. 
Coherex
Unlike the Watchman and Amplatzer Cardiac Plug, 
the Coherex WaveCrest device is deployed at the LAA 
orifice and can, therefore, be used in small-sized LAAs 
where the placement of other occluders might pose 
problems [7]. The device implantation was successful in 
96% of 63 patients with a complication rate of 2.7% [25]. 
Lariat
The Lariat device has been approved by the FDA for 
soft tissue approximation. Its efficacy for LAA closure 
was first studied in a series of 89 patients ineligible for 
oral anticoagulant therapy; 98% of the patients had 
complete LAA closure [2]. Subsequent multi-center 
register revealed successful deployment in 96 to 100% 
of patients. However, long-term observation of in over 
100 patients revealed both efficacy of the device and 
rare but severe complications such as hemopericardium 
and complete LAA detachment from the heart [11, 18, 
25, 32].
usually results in pharmacotherapy discontinuation. An 
argument for AF ablation is the ESC conclusion that, in 
patients with persistent and long-standing AF, ablation 
performed by an adequately trained and experienced 
operator is more effective than antiarrhythmic drug 
therapy [27]. However, this recommendation disre-
gards the age-related risk – it has been shown that 
the number of LAA occlusion complications increases 
considerably in patients over the age of 75 years [28]. 
The aim of AF ablation is to eliminate triggers for si-
nus rhythm disturbances resulting in atrial fibrillation. In 
90% of AF cases, the site of additional signal generation 
is the left atrial-pulmonary vein junction. Hence, pul-
monary vein isolation has become central for ablation 
approaches. Except for the site, ablation technique is 
also of importance, the most common being radiofre-
quency ablation, cryoablation, and ultrasound ablation. 
These techniques have comparable efficacy and high 
success rates, ie., 85% of patients undergoing ablation 
are free from atrial fibrillation within one year [29]. 
Nevertheless, other investigations have shown that pulmo-
nary vein isolation alone might not be sufficient [14, 30]. 
Di Biase et al. [30] assessed the effectiveness of 
electrical left atrial appendage isolation combined 
with extensive ablation (Group 1) and extensive abla-
tion alone (Group 2). A 12-month follow-up revealed 
a significant difference between the groups, ie., 56% 
and 28% of Group 1 and 2 patients, respectively were 
recurrence-free. Hence, the majority of Group 2 pa-
tients required a repeat procedure. Cumulative success 
at 24-month follow-up was reported in 76% of Group 
1 and 56% of Group 2 participants [30]. 
Percutaneous left atrial appendage occlusion  
— an alternative method of preventing 
thromboembolic complications in patients 
with atrial fibrillation 
Although oral anticoagulants have markedly dimin-
ished the rate of thromboembolism in patients with AF, 
a high risk of anticoagulation-related bleeding complica-
tions as well as difficulty in maintaining target INR levels 
resulted in a search for alternative treatment options [31]. 
Percutaneous left atrial appendage occlusion is among 
the possible solutions. 
PLAATO 
Percutaneous left atrial appendage transcatheter 
occlusion (PLAATO) was the first catheter-based device 
to be implanted in 2002 [31]. The annual stroke risk 
(3.8%) was lower than that expected based on CHADS2 
score (6.6%). However, despite the promising results, 
the device was withdrawn from the market due to the 
lack of funding [11, 12]. 
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LAmbre
The LAmbre system is a novel LAA occluder. Over 
180 human implants were performed in two clinical 
trials with 99.4% to 100% implant success. LAmbre 
implantation takes approximately 60 minutes [34]. 
During a 12-month follow-up, ischemic stroke occurred 
in 2 patients (1.3%) and major procedure-related 
complications in 5 patients (3.3%) [34, 35]. LAmbre 
left atrial appendage closure system received CE Mark 
certification in June 2016 indicating approval for use in 
the European Union.
Except for Lariat, all devices are inserted using 
femoral venous access with transseptal puncture under 
transesophageal echocardiographic guidance [32, 36] 
while Lariat device requires both transseptal puncture 
and epicardial access [18].
At present, the Amplatzer Cardiac Plug and Watch-
man are considered the most efficient among percuta-
neous LAA closure devices [5]. 
The Watchman and Lariat are the only two devices 
approved by the FDA for use in the United States. 
Lariat received FDA’s approval for soft tissue ligation. 
 PLAATO was initially approved by the but then with-
drawn from the market for commercial reasons [18]. 
All the above-mentioned devices received CE Mark-
ing and can Hus be used in EU member states. 
Hybrid therapy — a successful combination of 
catheter ablation and percutaneous left atrial 
appendage closure 
Patients at high risk for stroke might benefit from 
catheter ablation combined with percutaneous left atrial 
appendage closure (LAAC). Several studies have shown 
that Watchman occluder implantation performed in 
combination with catheter ablation did not significantly 
increase the peri-procedural risk [25, 37]. Left atrial 
appendage occlusion combined with radiofrequency 
ablation or cryoablation effectively eliminated AF in 
72% of patients [18]. 
Phillips et al. [37] observed that patients after 
ablation combined with successful implantation of the 
Watchman device had a 0.5% risk of ischemic stroke, 
which is a startling improvement compared to 4.5% 
calculated according to the CHADS2 scoring system. It 
can, therefore, be concluded that AF patients qualified 
for ablation are likely to benefit more from a combi-
nation of ablation and LAA occluder implantation [25]. 
Occluder-implanted patients may, in turn, experience 
additional improvement after ablation [38]. This con-
clusion is lent support by the results of a large multi-
centre registry including 349 patients, which revealed 
a decrease in the risk for stroke from an expected 
rate of 3.2% (CHA2DS2-VASc) to 0.9%. However, 
the predominant advantage of the hybrid therapy is 
a significant reduction in the incidence of procedure- 
-unre lated bleedings characteristic of patients with 
chronic OAC use [39, 40]. This is of particular impor-
tance as, in the study of Calvo et al. [40], the median 
HAS-BLED score in these patients was 3 points; hence 
clinically relevant bleeding might be expected in a large 
proportion of oral anticoagulant users [40]. 
Surgical left atrial appendage occlusion  
(during cardiac surgery)
There are three groups of non-pharmacological 
interventions for the prevention of venous thrombo-
embolism in patients with AF, i.e., the above-mentioned 
endocardial and epicardial closure of the left atrial 
appendage and surgical LAA exclusion. According to a 
meta-analysis performed by Tsai et al. [41], surgical LAA 
occlusion performed during cardiac surgery reduces the 
risk of thromboembolic complications and mortality 
should atrial fibrillation develop following surgery. LAA 
occlusion might also help decrease the risk for thrombo-
embolic events in patients undergoing cardiac surgery. 
An example might be mitral valve replacement in AF 
patients with or without LAA clot as well as in patients 
with sinus rhythm and LAA clot [42]. 
At 30-day follow-up, post-LAAO patients had 
a significant reduction in stroke incidence (0.95%) com-
pared to the non-LAAO group (1.9%). At the latest 
follow-up, the respective values were 1.4% and 4.1% 
[2, 41]. Nevertheless, numerous studies revealed that 
LAA occlusion might prove incomplete in 10–36% of pa-
tients resulting in life-threatening complications including 
stroke (newly formed thrombus might slip out through 
the existing gap and enter the circulation) [10, 43].
At present, surgical techniques for LAA exclusion 
comprise suture-closure of the LAA orifice, LAA exci-
sion with suture placement and amputating or non-am-
putating stapler exclusion [44]. Stapler exclusion yielded 
a higher proportion of complete LAA occlusion (72%) 
compared to suture closure (45%) [43]. There is much 
hope regarding the AtriClip LAA Exclusion System and 
TigerPaw II devices, but studies on the efficacy thereof 
are scarce [10]. 
A multicenter trial demonstrated the AtriClip Sys-
tem was a safe and effective device for LAA closure (no 
severe complications within a mean 36-month observa-
tion period); the risk of thromboembolic complications 
decreased to 0.5/100 patient-years from the expected 
stroke rate of 4.0/100 patient years based on individual 
CHA2DS2-VASc scores. Left atrial appendage AtriClip oc-
clusion can therefore be used in cardiosurgical patients 
at high risk for thromboembolic complications [44, 45].
Suwalski et al. [46] compared the efficacy of the 
AtriClip and TigerPaw II systems in patients under-
going coronary artery bypass grafting (CABG) and 
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concomitant left atrial epicardial ablation. Although 
TigerPaw II application was quicker and easier, it turned 
out unsuccessful in 25% of the patients. Ventosa-Fer-
nandez et al. [47] also reported a high proportion of 
TigerPaw II System’s malfunction. 
Pharmacoeconomic analysis of presently avail-
able modalities for prevention of thromboem-
bolic complications in atrial fibrillation 
Data obtained in the United States [48, 49] indicate 
that — from the pharmacoeconomic perspective - 
despite being the cheapest, warfarin proved the least 
cost-effective treatment strategy. Considering the rel-
atively early onset of several cardiovascular diseases, 
a long-term analysis should be employed. However, 
although a large patient cohort was analyzed using 
the Markov model, the mean observation period was 
below 3 years. Nevertheless, high stability of warfarin 
market and costs of single LAAO implementation caus-
es that these short-observation periods do not affect 
the reliability of long-term therapy cost estimation. It 
has been estimated that, relative to warfarin, LAAC is 
cost-effective at 7 years. By year 10, LAAC was dom-
inant over warfarin as, at this time point, the costs of 
warfarin treatment exceeded those of LAAC. Also, the 
number of quality-adjusted life-years (QALYs) gained 
with warfarin was lower compared to LAAC [48]. 
A cost-effectiveness analysis of NOACs is much 
more difficult as the expectation is that prices for the 
oldest types of NOACs (eg. dabigatran) will drop fol-
lowing patent expiry. Hence, estimations based on the 
present day prices are hardly reliable. LAAC has been 
shown to be superior over NOACs since it becomes 
cost-effective at 5 years. This time frame may extend 
once lower-priced generics enter the market; data 
update for the model will then be needed. LAAC will 
remain dominant over NOACs for a long time yet. In 
the model used, NOACs become cost-effective relative 
to warfarin but only at approximately 15 years and this 
will most probably hold for the recently developed 
NOACs. Of the available NOACs, apixaban has been 
shown to be the most cost-effective, but, as already 
mentioned, the expected drop in prices for the oldest 
types of NOACs might lead to their dominance over 
apixaban and other recent NOACs [48, 49].
Summing-up, irrespective of predicted changes in 
NOAC prices, LAAC is the most cost-effective therapy 
for prevention of thromboembolic complications in AF, 
and especially when the estimated survival time exceeds 
10 years. During that period LAAC becomes cost-effec-
tive relative to both warfarin and NOACs [48].
The choice of therapy should be determined by the 
patient’s condition and not financial considerations. 
However, the comparable efficiency of pharmacother-
apy and LAAC is a strong argument to always consider 
the latter — also for financial reasons. 
Owing to unavailability of relevant data, the above 
cost-effectiveness analysis does not include surgical 
LAA exclusion.
Summary
The main objective of modern antithrombotic 
pharmacotherapy is to minimize adverse effects of 
oral anticoagulants, and especially haemorrhagic com-
plications. The main challenge is the lack of antidotes 
or reversal agents for newly developed direct oral 
anticoagulants. 
Clinical experience has shown that numerous AF 
sufferers cannot undergo long- or even short-term 
anticoagulant therapy, which fact has created a niche 
for percutaneous left atrial appendage occlusion. The 
efficiency of occluder implantation is not lower than 
that of warfarin while the risk of bleeding is reduced 
and survival time increases. Hence, some extensions 
to the existing indications for LAAO might be worth 
considering. New devices with improved efficacy and 
safety continue being developed and introduced onto 
the market. 
A hybrid procedure, ie., a combination of cathe-
ter ablation and left atrial appendage closure, seems 
particularly promising. However, despite high pri-
mary efficacy, AF ablation alone is associated with 
a considerable risk of recurrent atrial fibrillation. 
Occluder-implanted patients are protected against 
thromboembolic events, should AF recur. According 
to CHA2DS2-VASc risk score, hybrid therapy of atrial 
fibrillation shows notably high efficacy. Nevertheless, 
there is a need for randomized clinical trials to com-
pare this treatment option with other methods used 
to prevent AF complications. 
In patients undergoing cardiac surgery for reasons 
other than AF, indications for surgical LAA occlusion 
include atrial fibrillation or LAA thrombus. A number 
of researchers suggest LAAO should be performed in 
all elderly patients undergoing cardiac surgery con-
sidering their high risk of developing AF. The AtriClip 
System outperforms other surgical modalities and can 
be applied during cardiac surgery as well as during 
thoracoscopy and mini-thoracotomy. 
The risk associated with combined catheter abla-
tion and left atrial appendage closure and surgical LAA 
occlusion increases slightly but is disproportionate 
in relation to LAA closure benefits. Furthermore, 
a pharmacoeconomic analysis indicates the superiority 
of LAAC over antithrombotic pharmacotherapy. 
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